Amicus plans to submit NDA to FDA for migalastat for fabry disease
Based on a series of discussions with and written communication received from the FDA, the Agency has informed Amicus that it may now submit an NDA for migalastat.
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.